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Abstract 
Introduction 
Canine atopic dermatitis (cAD) is a common, pruritic and allergic skin disease of dogs that 
shares several clinicopathological features with human atopic dermatitis (hAD). In hAD, 
periostin (PO) is assumed to play a critical role in the enhancement and chronicity of allergic 
skin inflammation; however, the pathogenesis of cAD involved of PO has been unknown. Also, 
the inducer of PO in the canine skin has not been clarified. Therefore in Chapter 1, the author 
investigated the expression of the PO protein and mRNA in healthy, atopic, and nonatopic 
inflamed skin in dogs. In Chapter 2, the author focused on IL-13 and TGF-β1 which were 
assumed to be inducing factor of PO, using skin tissues of cAD as well as canine cultured 
keratinocytes and dermal fibroblasts. Next, the function of PO was examined using culture 
canine keratinocytes by proliferation assay, microarray and real time quantitative RT-PCR.  
 
Chapter 1: Expression of Periostin in Normal, Atopic, and Nonatopic Chronically Inflamed 
Canine Skin 
The aim of this chapter was to examine the expression patterns of PO in healthy, atopic, and 
nonatopic chronically inflamed canine skin. Biopsy specimens from 47 dogs with skin disease, 
and normal skin tissue from 5 adult beagles were examined by light microscopy, 
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immunohistochemistry (IHC), and in situ hybridization (ISH). In normal skin, PO was localized 
just beneath the epidermis and around the hair follicles. In chronically inflamed skin, PO 
expression was most intense in the dermis with inflammatory cell infiltrates. In contrast, low 
levels of PO were detected in acutely inflamed and noninflamed skin. Conversely, all cAD 
tissues characteristically showed the most intense expression of PO in the superficial dermis. 
ISH showed that PO mRNA was broadly expressed in the basal epidermal keratinocytes, outer 
root sheath cells, and dermal fibroblasts in normal dog skin. High expression of PO mRNA was 
observed in fibroblasts in dog skin with chronically inflamed dermatitis. Moreover, in some 
chronically inflamed skin specimens, PO mRNA expression was increased in basal 
keratinocytes. The severity score of chronic pathological changes and CD3+ cell number in the 
dermis were correlated with distribution pattern of PO in the atopic skin. These data suggest that 
PO is able to play a role in the pathophysiology of chronic dermatitis, including cAD. 
 
Chapter 2: Involvement of IL-13 in the Induction of Periostin, and Effect of Periostin on 
Keratinocytes 
From the results of Chapter 1, it was suggested that PO might be involved in the pathogenesis 
of chronicity in cAD. Therefore, the author tried to clarify the mechanism of the amplification 
and chronicity of dermal inflammation by PO in canine atopic skin in this chapter. By 
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double-labeled ISH, IL-13 mRNA positive cells were detected near the keratinocytes and 
fibroblasts expressing PO mRNA in the dermis of atopic skin. TGF-β1 mRNA positive cell was 
not seen in all atopic skins. By in vitro assay, IL-13 induced the gene expression of PO in both 
canine dermal fibroblasts and keratinocytes. PO enhanced in vitro growth of canine 
keratinocytes. Moreover, among the PO-induced genes in cultured canine keratinocytes detected 
by microarray, the author identified IL-25 and KDAP as possible mediators in canine atopic skin. 
Also, real time PCR analysis revealed up-regulation of both IL-25 and KDAP gene expression 
in PO-stimulated keratinocytes. These data suggest that IL-13 possibly derived from Th2 cells 
stimulates PO production in both keratinocytes and fibroblasts, and then PO may play a critical 
role in the pathophysiology of cAD, especially in the enhancement and chronicity of skin lesion 
via IL-25 and KDAP. 
 
Conclusion 
The author proposed a novel hypothesis that PO induced by IL-13 contributes to the 
enhancement and chronicity of allergic skin inflammation in canine atopic skin. The findings of 
the present study provide a molecular basis for considering PO and IL-13 as a potential 
therapeutic targets for cAD. 
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General Introduction 
Atopic dermatitis (AD) is a chronic, pruritic and allergic skin disease in humans as well as 
animals, especially dogs. Classically, AD has been believed to associate with high specific IgE 
against environmental allergens, such as house dust mite (HDM). Recently, AD has been 
recognized as a multifaceted disease resulting from a complex interaction between 
environmental and genetic factors.  
Canine atopic dermatitis (cAD) has been focused as a spontaneous atopic animal model, 
because dogs live in human lifestyle environment, and cAD shares several clinicopathological 
features with human atopic dermatitis (hAD), including age of onset, skin areas affected, severe 
pruritus, and the immunopathological mechanism.[13, 18, 23] Histologically, the skin lesion in 
hAD and cAD is characterized by spongiotic dermatitis with mononuclear infiltrate composed 
of T lymphocytes. [19, 23] In addition, both hAD and cAD are characterized by allergic 
inflammation due to the release of various cytokines, mainly T helper 2 (Th2) cytokines such as 
interleukin (IL)-4 and IL-13.[18, 21, 23]  
In AD, once allergic inflammation is triggered by exposure to allergens, the skin lesion 
chronically persists without continuous allergen stimulation. Therefore, chronic inflammation 
irritation and epidermal hyperplasia are major pathological problems of hAD and cAD. 
However, the mechanisms underlying chronicity in allergic inflammation and associated skin 
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reaction remain unknown. 
Periostin (PO) is an extracellular matrix (ECM) protein that belongs to the fasciclin family.[15, 
20, 31] PO was first described as osteoblast-specific factor 2 (OSF-2) in 1993 as a homophilic 
adhesion molecule in bone formation.[25] PO modulates cell function by binding to integrin 
molecules on the cell surface; thus, providing signals for tissue development and remodeling.[6, 
20, 31, 32] The production of PO is induced by transforming growth factor (TGF)-β as well as 
interleukin-4 and IL-13, which are signature cytokines of the Th2-type immune response in 
bronchial asthma, suggesting the involvement of PO in allergic inflammation.[7, 14, 31] 
Recently, Masuoka et al.[14] reported that deficiency of PO suppressed allergic inflammation 
induced by treatment with HDM extract in atopic model mice. They further indicated that PO 
bound to αv integrin on mouse keratinocytes in vitro, which resulted in the induction of 
proinflammatory cytokines, including thymic stromal lymphopoietin (TSLP). Thus, PO may 
play a critical role in the enhancement and chronicity of allergic skin inflammation in hAD and 
experimental atopic models. However, only one report described a significant alteration of the 
gene expression of PO in atopic skin compared with healthy skin in dogs by real time reverse 
transcription polymerase chain reaction (RT-PCR).[29] 
In this study, the author tried to clarify the involvement of PO in canine atopic skin using skin 
tissues of cAD as well as canine cultured keratinocytes and dermal fibroblasts. The findings of 
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this study may provide a molecular basis for considering PO as potential therapeutic targets for 
cAD.  
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Chapter 1: Expression of Periostin in Normal, Atopic, and Nonatopic Chronically 
Inflamed Canine Skin 
 
Introduction 
PO is highly expressed in the skin of hAD patients and is correlated with disease severity on 
histological examination. Recently, using PO-deficient mice, Masuoka et al.[14] reported that a 
lack of PO results in failed development of allergic skin inflammation caused by sensitization to 
inhaled allergens. However no reports described the location of PO in canine health and atopic 
skin. 
 Previous in vitro analyses demonstrated that dermal fibroblasts produced and secreted PO, 
which is depending on cytokine stimulation via integrin signaling. In AD lesions, it is suspected 
that fibroblasts are the main source of PO, although it has not been confirmed by in vivo 
analysis.[14, 22, 26]  
It is important to reveal the localization of PO and PO producing cells in normal and affected 
skin, because we have to discuss the involvement of PO in canine atopic skin. First, the author 
examined the expression of the PO protein in healthy, atopic, and nonatopic inflamed skin in 
dogs. Then, the author examined the localization of PO mRNA by in situ hybridization (ISH) in 
these skin tissues. Finally, the author discussed a part of role of PO in the pathophysiology in 
canine atopic skin. 
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Materials and Methods 
RNA extraction from normal skin and other tissues, RT-PCR, TA cloning, Sequence analysis  
The normal canine tissues including heart, lung, liver, kidney, spleen, small intestine, large 
intestine, ovary, testis, cerebrum, lymphatic node and skin from two adult beagles (one male and 
one female, aged 1–7 years) were used as qualitative RT-PCR samples. Total RNA was 
extracted from normal tissues using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad, 
CA). Extracted total RNA was treated with RNase-free DNase (Promega, Madison, WI) and 
used in RT-PCR employing the SuperScript III First-Strand Synthesis System (Invitrogen Life 
Technologies). Primer sequences were obtained by determining the predicted mRNA sequences 
of Canis lupus familiaris PO (NCBI database accession number: XM_003433308). The primer 
sequences were as follows: canine PO forward, 
5’CAGCTCAGAGTCTTTGTCTATCGTACAG3’; and reverse, 
5’CTCCTGGTGTTAGGTGATAAAGGATG3’. PCR reaction with KOD FX Neo (Toyobo, 
Osaka, Japan) was performed as follows: denaturation at 94 °C for 5 min; 30 cycles of 
denaturation at 98 °C for 10 s, annealing at 66 °C for 30 s, and extension at 68 °C for 30 s; and a 
final extension step at 68 °C for 30 s.  
The gene fragment of skin was cloned into the pTA2 vector (Toyobo) using a TArget 
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clone-Plus-TA cloning kit (Toyobo). The partial sequences of PO were cloned into One Shot® 
TOP10 Chemically Competent Escherichia coli (Invitrogen Life Technologies). The precipitated 
DNA was sequenced and analyzed by TaKaRa Bio (Shiga, Japan) using a 3730xl DNA Analyzer 
(Applied Biosystems, Foster city, CA).  
 
Skin Biopsies 
The skin tissues obtained from the chest region of normal 5 dogs (two males and three females, 
aged 1–7 years) were used as controls (Azabu university experimental animal committee, 
No.100408-3).  
The clinical data and pathological diagnoses of 47 dogs of various breeds included in the 
present study are listed in Table 1. Their ages ranged from 4 months to 17 years, and the cohort 
included 27 males, 19 females, and one dog for which the sex was not documented. A total of 62 
biopsies were taken from the 47 dogs with skin diseases. Skin punch biopsies were fixed in 10% 
neutral-buffered formalin, embedded in parafﬁn, cut, and stained with hematoxylin and eosin 
(HE).  
The skin diseases included in the present study were divided into three groups: chronic 
dermatitis (inflammatory skin disease with acanthosis and dermal fibrosis) (case Nos. 1–41), 
acute dermatitis (case Nos. 42 and 43), and noninflamed skin disease (case Nos. 44–47). 
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Chronic skin diseases included cAD (n = 9), sebaceous adenitis (n = 4), superficial pyoderma (n 
= 2), pemphigus foliaceus (n = 2), deep pyoderma (n = 2), and sterile pyogranuloma (n = 2). 
The pathological diagnosis was based on clinical and light microscopic features. The diagnosis 
of cAD was based on the clinical criteria proposed by Terada.[27]  
Reverse transcription (RT) for real time PCR was performed on samples from 5 lesion sites of 
4 atopic dogs (site Nos. 3, 4, 7, 18, and 19). One half of each skin sample was fixed in 10% 
neutral-buffered formalin, embedded in parafﬁn, cut, stained with HE, and subjected to IHC and 
ISH. The second half of each specimen was embedded in optimal cutting temperature (OCT) 
compound (Sakura Finetek, Tokyo, Japan), and the block embedded in OCT compound was 
snap-frozen and maintained at −80 °C. Ten sections of each specimen, 10 μm in thickness, were 
cut on a cryostat at −20 °C and immersed into RNAse-free 1.5-ml microcentrifuge tubes 
containing Buffer RLT Plus (Qiagen, Hilden, Germany). Total RNA was extracted from each 
specimen using the RNeasy Plus Micro Kit (Qiagen). Extracted total RNA was used in 
quantitative RT-PCR employing the SuperScript® VILO™ cDNA Synthesis Kit (Invitrogen 
Life Technologies).  
 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed using the immunoenzyme polymer method and 
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the primary polyclonal or monoclonal antibodies shown in Table 2. After incubation with 4% 
BlockAceTM (Yukijirushi, Sapporo, Japan) for 10 min at room temperature, dewaxed sections 
were incubated overnight with the antibodies against PO at 4 °C. Peroxidase-conjugated 
anti-mouse (Histofine Simple Stain MAX-PO (M), Nichirei, Tokyo, Japan) or anti-rabbit 
(EnVision+
TM
, Dako Corp., Glostrup, Denmark) immunoglobulin (Ig)G were used as secondary 
antibodies. After the immunoreaction, the sections were colorized with diaminobenzidine 
(DAB) and counterstained with Mayer’s hematoxylin. Non-immune mouse or rabbit IgG was 
used in place of the primary antibody as a negative control.  
Immunofluorescence assay was performed using anti-type IV collagen, anti-laminin, and 
anti-PO antibodies. FITC-conjugated goat anti-rabbit IgG (EY Laboratories, San Maeto, CA) 
was used this assay. Immunofluorescence was analyzed using an FSX100 fluorescence 
microscope (Olympus, Tokyo, Japan). 
For quantitative morphometric analysis, the localization and distribution of PO were assessed 
within four areas of the skin: the epidermal–dermal junction (EDJ), which constitutes an 
anatomic functional unit containing the basement membrane; the perifollicular area (PF), 
including the follicular basement membrane and the connective tissue follicle; the superficial 
dermis (SD), the top layer of the dermis normally composed of thin collagen fibers; and the 
deep dermis (DD), the thin bottom layer of the dermis normally composed of thick collagen 
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fibers. Within each area, the expression of PO was assessed semiquantitatively and scored as 
follows: 0 = no expression, 1+ = weak expression, 2+ = moderate expression, 3+ = high 
expression. In cAD cases, the three distribution patterns of PO in the skin were defined, as 
follows (compared with the normal control, which was assigned a normal pattern): basement 
membrane (BM) pattern (weak-to-moderate expression in EDJ and PF); superficial pattern (high 
expression in EDJ or weak expression in SD); diffuse pattern (moderate expression in SD or 
expression in DD); as shown in Table 3. Epidermal thickness was measured; the number of 
CD3-positive cells (T cells), CD20-positive cells (B cells), and mast cells in the SD were 
counted in 10 randomly selected high-power fields for each sample and their average values 
were calculated. Dermal fibrosis was semiquantitatively assessed to evaluate the severity of 
chronic pathological changes as follows: no (0), mild (1+), moderate (2+), and severe (3+). 
 
In situ hybridization 
Gene-specific probe sets for canine mRNA consisting of an average of 20 different probe pairs 
were custom designed and synthesized by Affymetrix (Santa Clara, CA). PO probes were used 
in type 1/Fast Red. 
Single ISH for PO was performed on samples from 21 dogs (case Nos. 1–7, 10, 11, 15, 17, 18, 
21, 22, 24, 31, 32, 36, 37, 42 and 43) using the QuantiGene® ViewRNA ISH Tissue Assay 
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(Affymetrix) according to the manufacturer’s protocol. The signal for PO mRNA was visualized 
with fast red and counterstained with Gill’s hematoxylin. A canine PO mRNA sense probe or an 
ISH reaction solution without the probes was used as a negative control, according to 
Affymetrix’s recommendations. 
 
Real time quantitative RT-PCR 
Quantification of PO and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA 
expression was performed using StepOne™ Real-Time PCR Systems (Applied Biosystems) and 
TaqMan Universal PCR Master Mix (Applied Biosystems), with sample cDNA in a final 
volume of 20 μl per reaction. Canine PO mRNA primers and probes were designed by Applied 
Biosystems and supplied as TaqMan Gene Expression Assays Mix containing a 20× mix of 
unlabeled PCR forward and reverse primers, as well as a TaqMan MGB probe (Assay ID: 
Cf02680558_m1). The PCR reaction of PO mRNA was performed in duplicate for each sample 
and mean values of the gene expression were calculated as a ratio to those of GAPDH according 
to the ΔΔCT method.  
 
Statistical analyses 
Statistical analyses of distribution patterns of PO and histological scores were performed using 
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GraphPad Prism (ver. 5.0, GraphPad Software, La Jolla, CA). One-way ANOVA was performed 
to analyze the difference between distribution patterns of PO and histological scores, and 
significant differences were identified using the Tukey–Kramer test. Comparisons of mRNA 
extracted from between atopic and normal dog groups in analysis of PO mRNA expression were 
performed by the Mann–Whitney U-test. P values of <0.05 were considered statistically 
significant.  
 
Results 
Expression of the PO gene in normal skin tissues 
RT-PCR was performed to assess the expression level of the PO mRNA (346 bp) in various 
canine tissues, including heart, lung, liver, kidney, spleen, pancreas, small intestine, colon, ovary, 
testis, cerebrum, mesenteric lymph node and skin. The PO mRNA was expressed in a wide 
range of normal canine tissue (Figure 1a). Canine GAPDH (219 bp) cDNA was amplified as an 
internal control (Figure 1b). 
The sequence of PO mRNA extracted from canine skin was registered in the DNA Data Bank 
of Japan (DDBJ) (Accession number LC008358). Sequence analysis of the amplification 
product showed homology to the partial sequences of predicted canine PO mRNA (100%) and 
human PO mRNA (92%). 
ISH revealed that PO mRNA-positive cells were located in the outer root sheath (ORS), 
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particularly in the outer cells along the basement membrane, whereas there was a small number 
of signals in the ORS inner cells in normal dog skin (Figure 2a). The PO protein was located at 
the basement membrane of hair follicles in normal dog skin (score 1+) (Figure 2b). In the 
epidermis, PO mRNA was expressed only in the basal epidermal keratinocytes (Figure 2c). The 
PO protein was detected at low level in the EDJ (score 1+) (Figure 2d) but not in DD (score 0). 
The signals were not detected in tissues that underwent the procedure using the sense probe or 
the ISH solution without the probe (Figure 2e). PO protein was not detected in the cells. No 
specific staining was observed with non-immune rabbit IgG (Figure 2f). 
 
PO highly deposited in the atopic dermis. 
The results of the immunohistochemical examination of skin diseases are summarized in Table 
1. PO protein expression in chronically inflamed skin was most intense in the dermis with 
inflammatory cell infiltrates (scores 1+, 2+ or 3+) (Figures 3a, 3b, 4a, 4b, 5a, and 5b), whereas 
low levels of PO were detected in acutely inflamed and noninflamed skin diseases. Sebaceous 
adenitis was characterized by the destruction of the sebaceous gland and was associated with an 
intense expression of PO in the superficial dermis, particularly at PF. In diffuse dermatitis, PO 
protein expression was intense throughout the dermis. In sterile pyogranuloma, both 
inflammatory cells and PO protein expression were observed in DD and subcutaneous tissue. 
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Among the inflammatory skin diseases, all canine AD tissues characteristically showed the most 
intense expression of PO in the superficial dermis, particularly at EDJ (2+ or 3+) (Figure 6a). 
Expression of type IV collagen and laminin was detected at the EDJ and vascular basement 
membrane (Figure 7a, b). PO was more prominently expressed at the EDJ and detected faintly 
at the vascular basement membrane (Figure 7c). No staining was observed with non-immune 
rabbit IgG (Figure 6c).  
 
Keratinocytes and dermal fibroblasts are the main source of PO in cAD. 
Positive signals for PO mRNA were detected in spindle-shaped stromal cells in the 
inflammatory areas (Figures 3c, 4c, and 5c), together with protein expression. These stromal 
cells were positive for vimentin and negative for factor VIII-related antigen and smooth muscle 
actin, indicating that most of the stromal cells were fibroblasts. In addition, the PO mRNA was 
expressed in some adipocytes. In six (case Nos. 3, 5, 10, 15, 24, and 32) out of 21 dogs, 
increased PO mRNA expression was observed more clearly in epidermal keratinocytes (Figure 
6b). Signals were not detected in tissues that underwent the procedure using the sense probe or 
the ISH solution without the probe (Figure 6d). 
 
Real time RT-PCR using total RNA from frozen sections showed no significant difference in PO 
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mRNA expression between atopic and control skin groups. 
Real time RT-PCR using total RNA from sections of five lesion sites in 4 atopic dogs showed 
no significant difference in the ratio of PO/GAPDH mRNA expression between atopic and 
control skin groups (Figure 8). 
 
PO deposition score was correlated with histopathological severity of cAD. 
The distribution patterns of PO were correlated with chronic pathological changes and the 
number of CD3+ cells in the skin tissues of atopic dogs. Chronic pathological changes 
(epidermal thickening and fibrosis) and the number of CD3+ cells in the skin were significantly 
different between some distribution patterns of PO, especially in normal and diffuse patterns. 
Although there were no significant differences in the number of CD20+ cells and mast cells 
between the different distribution patterns of PO (Table 3 and Figure 9). 
 
Discussion 
To the best of my knowledge, this study was the first report showing the expression patterns of 
PO mRNA and protein in various spontaneous skin diseases of dogs. The author found that, in 
normal canine skin, similarly to that in human and murine skin, PO mRNA was expressed only 
in the basal epidermal keratinocytes, outer root sheath cells, and dermal fibroblasts and that PO 
was deposited just beneath the epidermis and around the hair follicles. Furthermore, the 
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distribution pattern of PO mRNA and protein in normal and inflamed skin appeared to be 
significantly different. An increased expression of PO was observed in chronically inflamed 
skin compared with normal, noninflamed, and acutely inflamed skin. In the present study, the 
author confirmed that cAD is characterized by the expression of PO in the superficial dermis, 
particularly at EDJ. PO was partially colocalized with other ECM such as type IV collagen and 
laminin components of the basement membrane. Moreover, the severity of chronic pathological 
changes and infiltration of CD3+ cells in the dermis were different between distribution patterns 
of PO, especially between normal and diffuse pattern. In atopic dogs, T cells are major 
components of the inflammatory cell infiltrate in the skin.[8] Th2 cytokines play a critical role 
in inducing allergic inflammation in addition to promoting IgE class switching.[18, 21, 23]  
The author has identified PO-producing cells within the canine atopic skin and proposes that 
these cells are fibroblasts. Conversely, in some atopic canine skin, PO mRNA was notably 
expressed in keratinocytes. Nishiyama et al.[16] showed that PO mRNA was temporarily 
expressed not only in fibroblasts but also in keratinocytes in hair follicles during wound healing. 
To the best of our knowledge, to date, no reports have focused on PO production by epidermal 
cells in human and canine atopic skin.[14, 22, 26, 31] 
Real time RT-PCR using total RNA from frozen sections, the ratio of PO/GAPDH mRNA 
expression did not differ significantly between atopic and normal dog groups. By real time 
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RT-PCR using sections, it was impossible to determine the distribution pattern of PO mRNA. As 
the number of PO non-producing cells (such as lymphocytes) was increased in atopic skin 
compared with control skin, it was difficult to compare PO gene expression.  
 In summary, the author has revealed the high expression of PO in canine atopic skin. PO is 
produced by keratinocyte and fibroblast and may play an important role in canine atopic skin. 
 
 
 
 
 
 
 
 
 
 
  
23 
 
Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.1. Identification of canine periostin (PO) and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) transcripts in various organs by reverse transcription polymerase chain reaction (RT-PCR). 
a. The PO mRNA was expressed in a wide range of normal canine tissue, including heart (He), lung 
(Lu), liver (Li), kidney (Ki), spleen (Sp), pancreas (Pa), small intestine (Si), colon (Co), ovary (Ov), 
testis (Te), cerebrum (Ce), mesenteric lymph node (Ly) and skin (Sk). b. Canine GAPDH cDNA was 
amplified as an internal control. M, molecular weight marker. 
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Figure 2. Normal skin, dog. a. The red color indicates a positive signal for PO mRNA (fast red) 
(arrow heads). The PO mRNA was expressed in the outer root sheath cells of the hair follicle, 
particularly in the outer cells along the basement membrane. In situ hybridization (ISH) for PO. 
Inset: high-power magnification view of hair follicles, ISH for PO. Bar = 500 μm. b. The brown 
color indicates positive staining for the PO protein (arrows). The PO protein was localized at the 
perifollicular area. Immunohistochemical staining (IHC) for PO. Inset: high-power magnification 
view of hair follicles, IHC for PO. Bar = 500 μm. c. In the epidermis, PO mRNA was expressed only 
in the basal epidermal keratinocytes (arrows heads). ISH for PO. d. Slight PO protein expression was 
observed in the dermis, just beneath the basal layer (arrows). IHC for PO. e. No signal was observed 
with the PO mRNA sense probe. ISH for PO (sense probe). f. No staining was observed with 
non-immune rabbit IgG. IHC for non-immune rabbit IgG. 500 
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Figure 3. Sebaceous adenitis, skin, dog, case No. 18. a. Isthmus perifollicular inflammation was 
observed. Hematoxylin and eosin (HE). Bar = 300 μm. b. PO protein expression was prominent in 
the perifollicular area. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in outer root 
sheath cells (arrows heads) and fibroblasts surrounding hair follicles. ISH for PO. Bar = 50 μm. 
Figure 4. Sterile pyogranuloma, skin, dog, case No. 32. a. Granulomatous inflammation was 
observed in the deep dermis and the subcutis. HE. Bar = 300 μm. b. PO was localized in 
inflammatory tissue. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in fibroblasts but 
not in inflammatory cells. Positive signals for PO mRNA were also detected in some adipocytes. 
ISH for PO. Bar = 50 μm. 
Figure 5. Diffuse dermatitis, skin, dog, case No. 22. a. Inflammatory cells were detected diffusely in 
the dermis. HE. Bar = 300 μm. b. PO protein expression was prominent throughout the dermis with 
inflammatory cell infiltrates. IHC for PO. Bar = 300 μm. c. The PO mRNA was expressed in 
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fibroblasts but not in inflammatory cells. ISH for PO. Bar = 50 μm. 
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Figure 6. Atopic dermatitis, skin, dog, case No. 5. a. The expression of PO was significantly 
elevated in the superficial dermis, particularly at the epidermal–dermal junction (arrows). IHC for 
PO. Inset: high-power magnification view of the epidermis and superficial dermis, IHC for PO. b. 
The PO mRNA was more prominently expressed in keratinocytes. ISH for PO. Inset: high-power 
magnification view of the epidermis and superficial dermis. c. No staining was observed with 
non-immune rabbit IgG. IHC for non-immune rabbit IgG. d. No signal was observed with the PO 
mRNA sense probe. ISH for PO (sense probe). Bar = 500 μm. 
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Figure 7. Atopic dermatitis, skin, dog, case No. 5. Epi, epidermis; Der, dermis. a. Expression of type 
IV collagen was detected at the epidermal–dermal junction (EDJ) (arrowheads) and vascular 
basement membrane (arrows). Immunofluorescence staining (IF) for type IV collagen. b. Expression 
of laminin was detected at the EDJ (arrowheads) and vascular basement membrane (arrows). IF for 
laminin. c. PO was more prominently expressed at the EDJ (arrowheads) and detected faintly at the 
vascular basement membrane. IF for PO. Bar = 100 μm. 
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Figure 8. PO/GAPDH mRNA rate in atopic skin (n = 5) and control skin (n = 5). The ratio of 
PO/GAPDH mRNA expression did not differ significantly between atopic and normal dog groups. 
Real time quantitative RT-PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
Figure 9. Correlation between distribution patterns of PO and histological severity in the skin tissues 
of atopic dogs. Three distribution patterns of PO of atopic dogs were as follows: basement 
membrane pattern, superficial pattern and diffuse pattern (compared with the healthy control, which 
was assigned a normal pattern). The number of inflammatory cells (CD3+, CD20+, and mast cells) 
in the dermis was counted in 10 high-power fields for each sample. Chronic pathological changes 
31 
 
(epidermal thickening and fibrosis) and the number of CD3+ cells in the skin was correlated between 
some distribution patterns of PO, especially between normal and diffuse pattern. Normal, normal 
pattern; BM, basement membrane pattern; Superficial, superficial pattern; Diffuse, diffuse pattern. 
(*p < 0.05, **p < 0.01, ***p < 0.001; one-way ANOVA). a. Epidermal thickness was measured in 
10 high-power fields for each sample. A significant positive correlation was observed between 
epidermal thickness and PO patterns b. Correlation between fibrosis scores and PO patterns. c. 
Correlation between the number of CD3-positive cells (T cells) and PO patterns. d. Correlation 
between the number of CD20-positive cells (B cells) and PO patterns. e. Correlation between the 
number of mast cells and PO patterns. 
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Table1. Characteristics of dogs with skin diseases and the results of immunohistochemical examinations of skin diseases. (continue)
EDJd PFe SDf DDg
1 1 Face Welsh Corgi C/13 y Superficial dermatitis AD 3+ 2+ 2+ 0
2 Back Superficial dermatitis AD 3+ 1+ 2+ 0
2 3 Face Shiba C/11 y Superficial dermatitis AD 3+ 2+ 1+ 0
4 Armpit Superficial dermatitis AD 3+ 2+ 2+ 1+
5 Hind leg Superficial dermatitis AD 3+ 2+ 1+ 0
3 6 Shoulder Bernese Mountain Dog M/9 y Superficial dermatitis AD/Non-lesion 2+ 2+ 0 0
7 Abdomen Superficial dermatitis AD/Lesion 2+ 2+ 1+ 0
8 Abdomen Superficial dermatitis AD/Non-lesion 2+ 2+ 0 0
4 9 Hind leg Golden Retriever S/10 y Superficial dermatitis AD 2+ 2+ 1+ 1+
10 Abdomen Superficial dermatitis AD 2+ 2+ 0 0
5 11 Abdomen Shiba M/8 y Superficial dermatitis AD 3+ 2+ 2+ 0
12 Abdomen Superficial dermatitis AD 3+ 2+ 0 0
6 13 Shoulder Chihuahua M/2 y Superficial dermatitis AD 2+ 1+ 0 0
14 Back Superficial dermatitis AD 3+ 1+ 0 0
7 15 Neck Shih Tzu F/5 y Superficial dermatitis AD 3+ 2+ 1+ 0
16 Armpit Superficial dermatitis AD 3+ 2+ 1+ 0
17 Back Superficial dermatitis AD 2+ 1+ 0 0
8 18 Back Yorkshire Terrier S/8 y Superficial dermatitis AD 2+ 1+ 0 0
9 19 Abdomen Standard Poodle M/4 y Superficial dermatitis AD 2+ 2+ 0 0
10 20 Abdomen Papillon S/10 y Superficial dermatitis Superficial pyoderma 2+ 2+ 0 0
21 Hind leg Superficial dermatitis Superficial pyoderma 2+ 1+ 0 0
11 22 Hip Shetland Sheepdog M/12 y Superficial dermatitis Superficial pyoderma/Lesion 3+ 2+ 1+ 0
23 Hip Superficial dermatitis Superficial pyoderma/Non-lesion 2+ 1+ 0 0
Comprehensive diagnosis/Remarksb
Immunohistochemical score and localization of periostinc
Case No.  Site No.  Site  Breed Sex/Agea Histological Diagnosis
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Table 1. Characteristics of dogs with skin diseases and the results of immunohistochemical examinations of skin diseases. (continue)
EDJd PFe SDf DDg
12 24 Back Golden Retriever M/13 y Demodicosis Demodicosis 3+ 2+ 0 0
13 25 Abdomen Miniature Dachshund C/10 y Superficial dermatitis Pemphigus foliaceus 2+ 1+ 0 0
14 26 Abdomen Miniature Dachshund S/14 y Superficial dermatitis Pemphigus foliaceus 2+ 1+ 0 0
27 Back Superficial dermatitis Pemphigus foliaceus 3+ 2+ 1+ 0
15 28 Hip Miniature Schnauzer M/11 y Superficial dermatitis Not AD 3+ 1+ 1+ 0
16 29 Neck Toy Poodle S/2 y Superficial dermatitis Unconfirmed 2+ 1+ 0 0
30 Back Superficial dermatitis Unconfirmed 2+ 1+ 0 0
17 31 Face Maltese M/8 y Superficial dermatitis Not AD 2+ 2+ 1+ 0
18 32 Unknown Akita S/5 y Sebaceous adenitis Sebaceous adenitis 1+ 2+ 0 0
19 33 Back Mixed M/5 y Sebaceous adenitis Sebaceous adenitis 2+ 3+ 1+ 0
20 34 Back Akita M/5 y Sebaceous adenitis Sebaceous adenitis 1+ 1+ 0 0
21 35 Back Akita M/7 y Sebaceous adenitis Sebaceous adenitis 3+ 2+ 0 0
22 36 Face Shiba S/1 y Diffuse dermatitis Deep pyoderma 2+ 2+ 2+ 1+
23 37 Nail bed French Bulldog S/5 y Diffuse dermatitis Deep pyoderma 1+ 1+ 1+ 1+
24 38 Face Mixed F/4 y Diffuse dermatitis Unconfirmed 3+ 2+ 1+ 2+
25 39 Face Pomeranian C/3 y Diffuse dermatitis Unconfirmed 1+ 2+ 1+ 1+
26 40 Face Akita C/10 y Diffuse dermatitis Unconfirmed 2+ 2+ 2+ 2+
27 41 Nail bed Mixed M/15 ｙ
Inflammatory granulation
tissue
Unconfirmed 1+ 2+ 1+ 1+
28 42 Back Miniature Dachshund C/11y Interface dermatitis Lesion 2+ 2+ 0 0
43 Back Interface dermatitis Non-lesion 1+ 1+ 0 0
29 44 Back Mixed F/17 y Interface dermatitis Unconfirmed 2+ 1+ 0 0
30 45 Unknown Basenji M/8 y Interface dermatitis Unconfirmed 1+ 1+ 0 0
31 46 Back Miniature Dachshund M/15 y Sterile pyogranuloma Sterile pyogranuloma 1+ 1+ 0 1+
32 47 Back Miniature Dachshund C/9 y Sterile pyogranuloma Sterile pyogranuloma 2+ 2+ 0 3+
Comprehensive diagnosis/Remarksb
Immunohistochemical score and localization of periostinc
Case No.  Site No.  Site  Breed Sex/Agea Histological Diagnosis
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Table 1. Characteristics of dogs with skin diseases and the results of immunohistochemical examinations of skin diseases. (continune)
EDJd PFe SDf DDg
33 48 Back Miniature Dachshund M/11 y
Superficial pustular
dermatitis
Superficial pustular drug reactions 1+ 2+ 1+ 0
34 49 Unknown Chihuahua S/3 y
Superficial pustular
dermatitis
Unconfirmed 1+ 1+ 0 0
35 50 Face Shetland Sheepdog M/4 m Dermatomyositis Dermatomyositis 1+ 1+ 0 1+
36 51 Foreleg Jack Russell Terrier S/2 y Folliculitis Unconfirmed 1+ 2+ 1+ 1+
37 52 Hind leg French Bulldog F/5 y Cutaneous mastocytosis Cutaneous mastocytosis 1+ 1+ 1+ 0
38 53 Foreleg Mixed M/4 y Vasculitis
Immune-mediated thrombocytopenia
with vasculitis
2+ 2+ 2+ 2+
39 54 Hip French Bulldog C/10 y Calcinosis cutis Calcinosis cutis 2+ 2+ 2+ 2+
40 55 Abdomen Labrador Retriever S/3 y Heat burn Heat burn 2+ 1+ 1+ 1+
41 56 Abdomen American Cocker Spaniel S/7 y Erythema caloricum Erythema caloricum 1+ 1+ 1+ 1+
42 57 Abdomen Maltese F/9 y Acute dermatitis Unconfirmed 1+ 1+ 0 0
43 58 Abdomen Maltese S/12 y
Acute febrile neutrophilic
dermatosis
Sweet's syndrome 1+ 1+ 0 0
44 59 Unknown Miniature Dachshund Unknown/7 m Edema Unconfirmed 1+ 1+ 0 0
45 60 Head Toy Poodle M/3 y Follicular dysplasia Follicular dysplasia 1+ 1+ 0 0
46 61 Hind leg West Highland White Terrier C/7 m Atrophy of hair follicles Alopecia 1+ 1+ 0 0
47 62 Hip Toy Poodle F/7 y Atrophy of hair follicles Iatrogenic cushing's syndrome 1+ 1+ 0 0
Comprehensive diagnosis/Remarksb
Immunohistochemical score and localization of periostinc
aM, male; F, female; C, castrated male; S, spayed female; y, years old; m, months old  bAD, atopic dermatitis; Unconfirmed, we could not show clinical diagnosis in some cases, because multiple differential diagnosis
could be considered or we couldn't obtain the satisfactory information from veterinary clinicians.  c0 = no expression, 1+ = mild expression, 2+ = moderate expression, 3+ = high expression in the dermis. dEDJ,  epidermal–
dermal junction ePD, perifollicular dermis fSD, superficial dermis gDD, deep dermis
Case No.  Site No.  Site  Breed Sex/Agea Histological Diagnosis
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Table 2. Primary antibodies and immunostaining protocol used in the current study.
Antibody Clone Dilution Source Antigen retrievala
Periostin Polyclonal 1:500 Abcam., Cambridge, U.K. No treatment
Type IV collagen Polyclonal 1:500 Tokyo Universityb Pepsin, 37°C, 30 min
Laminin Polyclonal 1:100 Progen Biotechnik., Heidelberg, Germany Pepsin, 37°C, 30 min
CD3 Polyclonal 1:50 Dako Denmark A/S., Glostrup, Denmark Pepsin, 37°C, 30 min
CD20 Polyclonal 1:400 Thermo fisher scientific., California, U.S.A. No treatment
Factor VIII-related
antigen
Polyclonal Prediluted Dako Denmark A/S., Glostrup, Denmark Pepsin, 37°C, 20min
SMAc 1A4 1:100 Dako Denmark A/S., Glostrup, Denmark No treatment
aPepsin = 0.4% pepsin (Sigma-Aldrich Co., St. Louis, MO, U.S.A.) bThis antibody was kindly supplied by Dr. M. Ito and Dr. K.
Arai (Department of Scleoprotein Chemistry and Cell Biology, Tokyo University of Agriculture and Technology). cSMA = smooth
muscle actin
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Table 3. Histological findings and periostin immunolabeling of tissue samples from atopic dogs.
Epidermal
thickness (μ
m)b
Fibrosisc
CD3 (cells/10
views)
CD20
(cells/10views
)
Mast cell
(cells/10views
)
EDJd,e PFd,f SDd,g DDd,h
Periostin
patterns i
1 1 Face 109.4 3+ 395 222 110 3+ 2+ 2+ 0 D
2 back 68.2 3+ 519 604 79 3+ 1+ 2+ 0 D
2 3 Face 78.2 2+ 45 35 82 3+ 2+ 1+ 0 S
4 Armpit 261.9 3+ 64 20 117 3+ 2+ 2+ 1+ D
5 Hind leg 70.5 1+ 53 41 55 3+ 2+ 1+ 0 S
3 6 Shoulder 18.7 0 2 6 15 2+ 2+ 0 0 BM
7 Abdomen 115.2 1+ 462 455 283 2+ 2+ 1+ 0 S
8 Abdomen 21.3 1+ 17 22 12 2+ 2+ 0 0 BM
4 9 Hind leg 283.2 3+ 192 27 217 2+ 2+ 1+ 1+ D
10 Abdomen 40 2+ 63 10 57 2+ 2+ 0 0 BM
5 11 Abdomen 95.1 1+ 20 14 83 3+ 2+ 2+ 0 D
12 Abdomen 41 1+ 23 51 113 3+ 2+ 0 0 S
6 13 Shoulder 58.4 1+ 159 3 161 2+ 1+ 0 0 BM
14 Back 106.3 1+ 69 25 54 3+ 1+ 0 0 S
7 15 Neck 134 3+ 82 5 40 3+ 2+ 1+ 0 S
16 Armpit 102.9 2+ 55 18 59 3+ 2+ 1+ 0 S
17 Back 141.4 2+ 68 17 53 2+ 1+ 0 0 BM
8 18 Back 64.1 2+ 22 34 21 2+ 1+ 0 0 BM
9 19 Abdomen 31.9 1+ 62 11 36 2+ 2+ 0 0 BM
Normal dog 15.3 ± 2.7j 0 3.8 ± 2.0j 1.2 ± 1.2j 17.2 ± 3.5j 1+ 1+ 0 0 N
a9 Dogs with AD underwent 19 sites all together. bEpidermal thickness, measured in 10 randomly selected fields for each sample. cSemiquantitative scores for
dermal fibrosis. d0 = no expression, 1+ = mild expression, 2+ = moderate expression, 3+ = high expression in the dermis. eEDJ, epidermal-dermal junction fPF,
perifollicular area gSD, superficial dermis hDD, deep dermis iDistribution patterns of periostin. N, normal patten; BM, basemant membrane pattern; S, superficial
pattern; D, diffuse pattern. jmean ± SD
 Site
Site
No.a
Dog
No.a
Histological Findings Periostin Immunolabeling
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Chapter 2: Involvement of IL-13 in the Induction of Periostin, and Effect of Periostin on 
Keratinocytes 
 
Introduction 
From the results of Chapter 1, it was suggested that PO might be involved in the pathogenesis 
of chronicity in cAD. Therefore, the author tried to clarify the mechanism of the amplification 
and chronicity of dermal inflammation by PO in canine atopic skin in this chapter. 
Firstly, the author focused on IL-13 and TGF-β1 which were assumed to be inducing factor of 
PO, using skin tissues of cAD as well as canine cultured keratinocytes and dermal fibroblasts.  
It is widely known that TGF-β is a major trigger of PO production of both dermal and 
pulmonary fibroblasts.[4, 24, 32] Recently, Masuoka et al.[14] reported that IL-13 induced PO 
production in the skin of a murine atopic model independently of TGF-β.  
Next, the author examined the function of PO using culture canine keratinocytes by 
proliferation assay, microarray and real time quantitative RT-PCR. The keratinocytes acts as 
major immune cells as well as a mechanical barrier between the external environment and the 
body.[10, 12] Previous studies have reported that cytokines and chemokines such as thymus and 
activation-regulated chemokine (TARC/CCL17) are exclusively produced by keratinocytes in 
human and canine atopic skin.[10, 12] From the results of immunohistochemistry in Chapter 1, 
the author assumed that PO might involve the epidermal thickening and infiltration of 
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inflammatory cells which are major pathologic features in canine atopic skin.  
Finally, the author discussed the possible involvement of PO in the pathophysiology of cAD. 
 
Materials and Methods 
Double-In situ hybridization 
Double-ISH for PO and IL-13/ TGF-β1 was performed using the QuantiGene® ViewRNA ISH 
Tissue Assay according to the manufacturer’s protocol, as described Chapter 1. PO probes were 
used in type 1/Fast Red, and IL-13 and TGF-β1 were used in type 6/Fast Blue. Double-ISH 
sections were counterstained with Mayer's hematoxylin.  
 
Cell culture of canine keratinocytes and dermal fibroblasts 
The author used two types of culture cells, commercially available canine keratinocyte cell line 
(CPEK, CELLnTEC Advanced Cell Systems, Bern, Switzerland) and canine dermal fibroblasts.  
CPEK was cultured in 25 cm
2
 flasks (AGC TECHNO GLASS CO.,LTD., Shizuoka, Japan) in 
CnT-09 (CELLnTEC Advanced Cell Systems) with 10% fetal bovine serum (FBS; Hana-nesco 
Bio. Co., Tokyo, Japan) and 1% Antibiotic Antimycotic (Thermo Fisher Scientific Inc., Waltham, 
MA) until approximately 80% confluence at 37 °C under 5% CO2. The cultured cells were 
trypsinized by treatment with 2 ml Trypsin-EDTA and incubated for 7–10 min at 37 °C. Fifth- to 
tenth-passage CPEK was used in these experiments.  
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Primary culture of canine dermal fibroblasts was performed according to the previous report 
[1] for the human skin. Briefly, full-depth skin samples obtained from the chest region of 
normal dogs were immediately placed in PBS (pH 7.2, 0.01 M) with 1% Antibiotic Antimycotic. 
Skin samples were rinsed seven times with PBS. Then skin samples were fragmented into 5 
mm
2
 pieces. These skin fragments were laid onto the surface of 60 mm x 15mm Petri dishes 
with Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/ F12, 1:1; Invitrogen 
Life Technologies) containing of 10% fetal bovine serum and 1% Antibiotic Antimycotic. 
Cultures were incubated at 37°C in a humidified incubator with 5% CO2. The culture medium 
was changed every three days. Satisfactory proliferation of fibroblasts was observed in 
approximately twenty days. Fibroblasts of 3rd to 5th passages were used for the experiments.  
 
Real time quantitative RT-PCR 
CPEK and dermal fibroblasts were grown in 24-well plates (AGC TECHNO GLASS 
CO.,LTD.); after washing with PBS to remove all sera, then the cells were serum-starved for 
24hrs.  
For real time quantitative RT-PCR analysis to estimate PO mRNA expression, CPEK and 
fibroblasts were cultured in DMEM/F12 with or without 50ng/μL recombinant canine IL-13 
(rcIL-13: R&D Systems, Minneapolis, MN) for 6 or 24 hrs. CPEK were cultured in DMEM/F12 
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with or without 2µg/mL recombinant human PO (rhPO, R&D Systems) for 2, 6, 12, 24 or 36 
hrs.  
After stimulation by rcIL-13 or rhPO, total RNA was extracted from cell cultures using the 
RNeasy Plus Micro Kit. Extracted total RNA was used for RT-PCR employing the 
SuperScript® VILO™ cDNA Synthesis Kit. Quantification of mRNA expression was 
performed using StepOne™ Real-Time PCR Systems, TaqMan Universal PCR Master Mix and 
TaqMan MGB probe for the target genes: PO, GAPDH, IL-25 (assay ID, Cf02643291_m1), 
keratinocyte differentiation-associated protein (KDAP) (assay ID, Cf02680558_m1), as 
described in Chapter 1. The PCR reaction was performed in duplicate for each sample and mean 
values of the target gene expression were calculated as a ratio to those of GAPDH according to 
the ΔΔCT method.  
 
Proliferation Assay 
For proliferation assay, CPEK was cultured in with DMEM/F12 supplemented with 0.1% FBS 
and either rhPO (1 or 4µg/mL) dissolved in PBS or PBS alone for 24 hrs. After stimulation, 
proliferation assay was performed using a cell-counting kit-8 (CCK-8; Dojindo Molecular 
Technologies, Kumamoto, Japan) according to the manufacturer’s protocol.[11]  
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Microarray 
For DNA microarray analysis, CPEK was cultured with or without 4µg/mL rhPO for 6 or 24 
hrs. After stimulation by rhPO, total RNA was extracted from cell cultures using the RNeasy 
Plus Micro Kit. The microarray analyses were done by DNA Chip Research Inc. (Yokohama, 
Japan) using the Canine (V2) Gene Expression Microarray (4x44k, two-color array) according 
to Agilent microarray DNA chip analysis. cRNA was synthesized from the mRNA component 
of total cellular RNA. Each cRNA sample was then independently labeled with Cy3 (green) and 
Cy5 (red). The fold change was calculated for samples to represent a ratio of expression 
between stimulated and unstimulated control samples.  
 
Statistical analyses 
Statistical analyses in real time quantitative RT-PCR and proliferation assay were performed 
using GraphPad Prism. Comparisons of mRNA between extracted samples from stimulated and 
unstimulated cells were performed by the unpaired T test. P values of <0.05 were considered 
statistically significant.  
 
Results 
IL-13 mRNA positive cells were present near the PO mRNA-positive cells. 
By Double-ISH, the IL-13 mRNA-positive small round cells were detected around the PO 
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mRNA-positive keratinocytes and fibroblasts in the dermis of atopic skin (Figure 10). TGF-β1 
mRNA-positive cell was not seen in all atopic skins. 
 
IL-13 stimulated both keratinocytes and fibroblasts to produce PO. 
By in vitro experiments, following 6 and 24hr treatment of rcIL-13, expression of PO mRNA 
in keratinocytes was significant increased compared with unstimulated cells (Figure 11a). 
Following 24hr treatment of rcIL-13, expression of PO mRNA in dermal fibroblasts was 
significant increased compared with unstimulated cells (Figure 11b). 
 
PO enhanced in vitro growth of canine keratinocyte cell. 
The effect of PO on growth of keratinocytes was evaluated using CPEK. In vitro growth of 
CPEK was enhanced by 4µg/ml of PO treatment (Figure 12). 
 
PO induced gene expression of IL-25 and KDAP of canine keratinocyte cell. 
The microarray data discussed in this article have been deposited in NCBIs Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series 
accession number GSE77041. Among these genes, the author focused on IL-25 and KDAP, 
because previous studies reported that these genes were shown to be overexpressed in chronic 
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allergic dermatitis.[9, 30] 
For validation of microarray results, the author performed real time quantitative RT-PCR for 
the IL-25 and KDAP. Following 36hr treatment with rhPO, expression of IL-25 mRNA in 
keratinocytes was significant increased compared with an unstimulated cells (Figures 13). 
Following 2hr treatment with rhPO, expression of KDAP mRNA in keratinocytes was 
significant increased compared with an unstimulated cells (Figures 14). 
 
Discussion 
Previous studies have shown that cAD is associated with overproduction of Th2 cytokines 
such as IL-13.[18, 21, 23] By double-labeled ISH, IL-13 mRNA positive cells suspected as 
lymphocytes were detected near the keratinocytes and dermal fibroblasts expressing PO mRNA 
in canine atopic skin. This indicates close relationship between these two types of cells in canine 
atopic skin. These results strongly suggest that IL-13 induce PO production in keratinocytes and 
dermal fibroblasts in canine atopic skin independently of TGF-β1. To the best of my knowledge, 
this paper was the first report indicating the relationship between PO and IL-13 in spontaneous 
atopic skin.  
The author revealed a part of functional roles of PO to induce the enhancement and chronicity 
in canine atopic skin by in vitro experiments. Firstly, the author confirmed that rhPO enhanced 
in vitro growth of canine keratinocyte cell. Moreover, among the PO-induced genes detected by 
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microarray, the author firstly identified IL-25 and KDAP as possible mediators in spontaneous 
atopic skin. Because, qRT-PCR analysis revealed up-regulation of both IL-25 and KDAP gene 
expression in PO-stimulated keratinocytes compared to unstimulated control.   
IL-25 (also known as IL-17E) is important for Th2-mediated immunity in a murine model of 
asthma, and induces the impaired skin barrier observed in AD patients.[5, 9, 28] The level of 
IL-25 mRNA has been revealed to be elevated in the lungs of asthmatic patients and in the skins 
of hAD patients).[28] Furthermore, compared to PO wild-type mice, PO null mice showed 
amelioration of in HDM-induced inflammation and mucous metaplasia, as well as reduced Th2 
cytokines including IL-25 mRNA expression.[2] Together with these previous studies, the 
author suspects that PO enhances Th2- immunoreaction via IL-25 signaling in canine atopic 
skin.  
PO has been reported to play a role to enhance proliferation and differentiation of 
keratinocytes by in vitro and in vivo experiments. Deficiency or blockage of PO suppressed 
acanthosis by transdermal treatment with HDM extract in atopic model mice. In the present 
study, for validation of microarray results, we performed quantitative RT-PCR analysis, and 
found temporary up-regulation of keratinocyte differentiation-associated protein (KDAP) gene 
expression in rPO-stimulated keratinocytes compared to unstimulated control at 2 hr after 
sensitization (Supplemental material 2). KDAP (encoded by KRTDAP) is a recently identified 
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secretory protein that may play as a soluble regulator for the differentiation of keratinocytes. 
Yagihara et al.[30] reported that KDAP was more widely spread in the spinous layers of the 
epidermis in chronic allergic dermatitis compared to normal skin in dogs. Acanthosis is a typical 
histopathological features of hAD and cAD. We suspected that KDAP induced by PO may play 
a role in acanthosis of canine atopic skins.  
Despite treatment with inhaled glucocorticoids or cyclosporin, several dogs of cAD continue to 
have uncontrolled skin lesion that requires more intensive therapy.[17] PO may contribute to the 
enhancement and chronicity of allergic skin inflammation by activating keratinocytes and 
dermal fibroblasts in the absence of environmental allergens as shown in the study. Corren et 
al.[3] examined patients with poorly controlled asthma treated with lebrikizumab, which is a 
monoclonal antibody to IL-13. Patients with high pretreatment levels of serum PO had greater 
clinical improvement than patients with low PO levels. Furthermore, the serum levels of PO 
were significantly elevated in hAD patients compared with controls.[14] These facts suggest 
close relationship between IL-13 and PO in hAD.  
The author suspects that PO may play an important role in the pathophysiology of cAD. The 
data in this study suggest that IL-13 possibly derived from Th2 cells stimulates PO production 
in both keratinocytes and fibroblasts, and then PO may contribute to the enhancement and 
chronicity of cAD via IL-25 and KDAP (Figure 15). The findings of the present study provide a 
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molecular basis for considering AD. Based on the results of this study, further in vivo studies 
using experimental atopic dogs may provide novel therapeutic targets focusing on PO, IL-13 
and IL-25 for AD. 
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Figures and Tables 
 
Figure 10. Atopic dermatitis, skin, dog, case No. 5. The interleukin (IL)-13 mRNA-positive cells 
(arrows) are detected around the PO mRNA-positive cells in the atopic skin. Double-ISH for PO and 
IL-13. Bar = 50 μm. 
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Figure 11. Recombinant IL-13 induced expression of PO mRNA in both canine dermal fibroblasts 
and keratinocytes. Quantitative analysis of mRNA levels of PO in the cultured keratinocytes and 
dermal fibroblasts at the indicated time 6 and 24 hrs after sensitization with IL-13. a. Following both 
6 and 24hrs of IL-13 treatment, PO mRNA expression in keratinocytes was significant increased 
compared with vehicle control. b. Following 24hr of IL-13 treatment, PO mRNA expression in 
dermal fibroblasts was significant increased compared with vehicle control. Real time quantitative 
RT-PCR (**P < 0.01, ***P < 0.001; vs vehicle control; unpaired t-test). 
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Figure 12. Proliferation assay of canine keratinocyte cell line (CPEK) with or without recombinant 
PO. In vitro growth of CPEK was enhanced by 4µg/ml of PO treatment (*P < 0.05, vs vehicle 
control; unpaired t-test). 
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Figure 13. Recombinant PO induced expression of IL-25 mRNA in canine keratinocytes. 
Quantitative analysis of mRNA levels of PO in the cultured keratinocytes at the indicated time 2, 6, 
12, 24 and 36 hrs after sensitization with PO. Following 36 hrs of PO treatment, IL-25 mRNA 
expression in keratinocytes was significant increased compared with vehicle control. Real time 
quantitative RT-PCR (**P < 0.01; vs vehicle control; unpaired t-test). 
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Figure 14. Recombinant IL-PO induced expression of KDAP mRNA in canine keratinocytes. 
Quantitative analysis of mRNA levels of PO in the cultured keratinocytes and dermal fibroblasts at 
the indicated time 2, 6, 12, 24 and 36 hrs after sensitization with PO. Following 2hrs of PO treatment, 
KDAP mRNA expression in keratinocytes was significant increased compared with vehicle control. 
Real time quantitative RT-PCR (*P < 0.05; vs vehicle control; unpaired t-test). 
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Figure 15. The schema indicates hypothesis on the chronicity of inflammation via PO in atopic skin. 
The data in this study suggest that IL-13
1)
 possibly derived from Th2 cells stimulates PO 
production
2)
 in both keratinocytes and fibroblasts, and then PO
3)
 may be involved a critical role in 
the enhancement and chronicity of cAD via IL-25 and KDAP
4)
. APCs, antigen-presenting cells. 
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Conclusion 
The author proposed a novel hypothesis that PO contributes to enhancement and chronicity of 
allergic skin inflammation in canine atopic skin. The new findings on cAD from this study are 
summarized as follows.  
 
1. Canine atopic skin characteristically showed intense expression of PO in the superficial 
dermis. The severity score of chronic pathological changes and CD3+ cell number in the dermis 
were correlated with distribution pattern of PO in the canine atopic skin. These results indicated 
that PO could play a role in the pathophysiology of cAD. 
 
2. ISH showed that fibroblasts and keratinocytes were the main source of PO in cAD. To the 
best of our knowledge, to date, no reports have focused on PO production by keratinocytes in 
both human and canine atopic skin. 
 
3. By double-labeled ISH, IL-13 mRNA positive cells were detected near the keratinocytes and 
fibroblasts expressing PO mRNA in the dermis of atopic skin. TGF-β1 mRNA positive cell was 
not seen in all atopic skins. By in vitro assay, IL-13 induced the gene expression of PO in both 
canine dermal fibroblasts and keratinocytes. These results indicated that IL-13 induce PO 
production in keratinocytes and dermal fibroblasts in canine atopic skin independently of 
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TGF-β1. 
 
4. PO enhanced in vitro growth of canine keratinocytes, suggesting that PO could be an 
important factor of pathogenesis of acanthosis in cAD.  
 
5. PO induced gene expression of IL-25 and KDAP of canine keratinocyte cell. The author 
suggested IL-25 and KDAP as possible mediators in canine atopic skin.  
 
In summary, the author proposes that IL-13 possibly derived from Th2 cells stimulates PO 
production in both keratinocytes and fibroblasts, and then PO may play a critical role in the 
pathophysiology of cAD, especially in the enhancement and chronicity of skin lesion via IL-25 
and KDAP. The findings of the present study provide a molecular basis for considering PO and 
IL-13 as a potential therapeutic targets for cAD. 
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